A Study to Learn About How Women Metabolize and Respond to Opioids When Used for Managing Post-operative Pain


About this study

The goal of this study is to examine the current and (potential) future therapeutic relevance of PGx testing for surgical ovarian cancer patients in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of opioid medications.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Patients 18 years or older.
  • A Mayo Clinic patient with a planned laparotomy for gynecologic pathology including patients who have received neoadjuvant chemotherapy. 
  • Patients must understand and provide written informed consent and HIPAA authorization prior to initiation of any study-specific procedures.
  • Patient is willing to engage in a medication assessment as part of their clinical visit preparation (when needed).

Exclusion Criteria

  • Patient with uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.
  • Pregnant patients.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Gretchen Glaser, M.D.

Closed for enrollment

Contact information:

Karen Ishitani R.N.



More information


Publications are currently not available

Mayo Clinic Footer